Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome.

Kaplan LD, Shiramizu B, Herndier B, Hahn J, Meeker TC, Ng V, Volberding PA, McGrath MS. Influence of molecular characteristics on clinical outcome in human immunodeficiency virus-associated non-Hodgkin's lymphoma: identification of a subgroup with favorable clinical outcome. Blood. 1995 Apr 01; 85(7):1727-35.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Bleomycin
Blotting, Southern
CD4 Lymphocyte Count
Clone Cells
Combined Modality Therapy
Cyclophosphamide
Cytarabine
Dexamethasone
DNA, Neoplasm
DNA, Viral
Doxorubicin
Etoposide
Gene Rearrangement, B-Lymphocyte, Heavy Chain
Genes, Immunoglobulin
Genes, myc
Granulocyte-Macrophage Colony-Stimulating Factor
Herpesvirus 4, Human
Humans
Immunoglobulin Variable Region
Immunologic Factors
Leucovorin
Life Tables
Lymphoma, AIDS-Related
Lymphoma, Non-Hodgkin
Methotrexate
Polymerase Chain Reaction
Prednisone
Proportional Hazards Models
Radiotherapy, Adjuvant
Recombinant Proteins
RNA, Messenger
RNA, Neoplasm
Survival Analysis
Treatment Outcome
Vincristine

authors with profiles

Bruce Shiramizu, MD

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support